Literature DB >> 22247384

Comparing ONRAB® AND RABORAL V-RG® oral rabies vaccine field performance in raccoons and striped skunks, New Brunswick, Canada, and Maine, USA.

Christine Fehlner-Gardiner1, Robert Rudd, Dennis Donovan, Dennis Slate, Libby Kempf, Jacqueline Badcock.   

Abstract

Control of rabies in mesocarnivore reservoirs through oral rabies vaccination (ORV) requires an effective vaccine bait. Oral rabies vaccine performance in the field may be affected by a variety of factors, including vaccine bait density and distribution pattern, habitat, target species population density, and the availability of competing foods. A field study in which these covariates were restricted as much as possible was conducted along the international border of the state of Maine (ME), USA, and the province of New Brunswick (NB), Canada, to compare the performance of two oral rabies vaccines in raccoons (Procyon lotor) and striped skunks (Mephitis mephitis). RABORAL V-RG(®) (vaccinia-rabies glycoprotein recombinant oral vaccine in fishmeal-coated sachet) or ONRAB(®) (adenovirus-rabies glycoprotein recombinant oral vaccine in Ultralite bait matrix) were distributed in ME and NB, respectively, by fixed-wing aircraft at a density of 75 baits/km(2) along parallel flight lines spaced 1.0 km apart. Sera were collected from live-trapped raccoons and skunks 5-7 wk post-ORV and assayed to determine antibody prevalence in each area. Duplicate serum samples were provided blind to two different laboratories for analyses by rabies virus serum neutralization assays (at both laboratories) and a competitive enzyme-linked immunosorbent assay (at one laboratory). There was no significant difference in the proportion of antibody-positive animals determined by the three serologic methods, nor was there a significant difference between ONRAB and RABORAL V-RG in the proportion of antibody-positive striped skunks observed post-ORV. In contrast, the proportion of antibody-positive raccoons was significantly higher in the ONRAB- versus the RABORAL V-RG-baited areas (74% vs. 30%; χ(2)=89.977, df=5, P<0.0001). These data support that ONRAB may serve as an effective tool for raccoon rabies control.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22247384     DOI: 10.7589/0090-3558-48.1.157

Source DB:  PubMed          Journal:  J Wildl Dis        ISSN: 0090-3558            Impact factor:   1.535


  24 in total

1.  Modeling pre-existing immunity to adenovirus in rodents: immunological requirements for successful development of a recombinant adenovirus serotype 5-based ebola vaccine.

Authors:  Jin Huk Choi; Stephen C Schafer; Lihong Zhang; Terry Juelich; Alexander N Freiberg; Maria A Croyle
Journal:  Mol Pharm       Date:  2013-08-19       Impact factor: 4.939

2.  Rabies surveillance in the United States during 2011.

Authors:  Jesse D Blanton; Jessie Dyer; Jesse McBrayer; Charles E Rupprecht
Journal:  J Am Vet Med Assoc       Date:  2012-09-15       Impact factor: 1.936

3.  Serological Responses of Raccoons and Striped Skunks to Ontario Rabies Vaccine Bait in West Virginia during 2012-2016.

Authors:  Shylo R Johnson; Dennis Slate; Kathleen M Nelson; Amy J Davis; Samual A Mills; John T Forbes; Kurt C VerCauteren; Amy T Gilbert; Richard B Chipman
Journal:  Viruses       Date:  2021-01-22       Impact factor: 5.048

4.  Application of recombinant adenoviruses expressing glycoprotein or nucleoprotein of rabies virus to Korean raccoon dogs.

Authors:  Jiyoung Choi; Dong-Kun Yang; Ha-Hyun Kim; Hyun-Ye Jo; Sung-Suk Choi; Jong-Taek Kim; In-Soo Cho; Hee-Won Kim
Journal:  Clin Exp Vaccine Res       Date:  2015-07-29

5.  A behaviorally-explicit approach for delivering vaccine baits to mesopredators to control epizootics in fragmented landscapes.

Authors:  James C Beasley; Todd C Atwood; Michael E Byrne; Kurt C Vercauteren; Shylo R Johnson; Olin E Rhodes
Journal:  PLoS One       Date:  2015-01-14       Impact factor: 3.240

6.  Safety and immunogenicity of recombinant rabies virus (ERAGS) in mice and raccoon dogs.

Authors:  Dong-Kun Yang; Ha-Hyun Kim; Sung-Suk Choi; Jong-Tack Kim; Kang-Bok Lee; Seong Heon Lee; In-Soo Cho
Journal:  Clin Exp Vaccine Res       Date:  2016-07-29

Review 7.  Oral vaccination of wildlife using a vaccinia-rabies-glycoprotein recombinant virus vaccine (RABORAL V-RG®): a global review.

Authors:  Joanne Maki; Anne-Laure Guiot; Michel Aubert; Bernard Brochier; Florence Cliquet; Cathleen A Hanlon; Roni King; Ernest H Oertli; Charles E Rupprecht; Caroline Schumacher; Dennis Slate; Boris Yakobson; Anne Wohlers; Emily W Lankau
Journal:  Vet Res       Date:  2017-09-22       Impact factor: 3.683

8.  The present and future of rabies vaccine in animals.

Authors:  Dong-Kun Yang; Ha-Hyun Kim; Kyung-Woo Lee; Jae-Young Song
Journal:  Clin Exp Vaccine Res       Date:  2013-01-15

9.  A single immunization with recombinant rabies virus (ERAG3G) confers complete protection against rabies in mice.

Authors:  Dong-Kun Yang; Keisuke Nakagawa; Naoto Ito; Ha-Hyun Kim; Bang-Hun Hyun; Jin-Ju Nah; Makoto Sugiyama; Jae-Young Song
Journal:  Clin Exp Vaccine Res       Date:  2014-06-20

10.  Oral immunization of mice with recombinant rabies vaccine strain (ERAG3G) induces complete protection.

Authors:  Dong-Kun Yang; Ha-Hyun Kim; Sung-Suk Choi; Jong-Taek Kim; Woong-Ho Jeong; Jae-Young Song
Journal:  Clin Exp Vaccine Res       Date:  2015-01-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.